Biden Orders Review of Marijuana’s Classification
On October 6, as President Biden moved to pardon all prior federal offenses for possession of marijuana, he also directed HHS and the attorney general to review marijuana’s current classification as a schedule I drug. Read more here and here.

CDC Study on E-Cigarette Use By Middle and High School Students in 2022
A new CDC survey released October 6 found that nearly 2.6 million middle and high school students in the U.S. reported using e-cigarettes in 2022. Read more here.

Cognitive Side Effects of Cannabis-Based Medicines
According to a study published in Systematic Reviews, cannabinoid-based medicines may have negative impacts on patients’ cognitive function, but that impact appears to be minor. Read more here.

DOJ, FDA Pursue Injunctions for Six E-Cigarette Makers
The Department of Justice is pursuing permanent injunctions against six e-cigarette manufacturers on behalf of the Food and Drug Administration. The move marks the first time the FDA has initiated injunction proceedings to enforce its premarket review requirements for new tobacco products. Read more here.

Report Warns of Dangers of Hemp Intoxicants
According to a new report from the California Cannabis Industry Association, state and federal authorities need to do more to reign in the booming market for intoxicating hemp products. Read more here.

Reps. Kuster and Trahan Call on Biden Administration to Support Audio-Only Telehealth Flexibility for Opioid Addiction Treatment
On October 14, Reps. Ann Kuster (D-NH) and Lori Trahan (D-MA) sent a letter to the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) to request an extension of temporary telehealth flexibilities for the treatment of opioid use disorder. Read more here.

Booker Releases Legislation Requiring Scientific and Medical Studies to Develop Treatments for Opioid Overdoses
On October 13, Senator Cory Booker (D-NJ) announced the Temporary Emergency Scheduling and Testing (TEST) of Fentanyl Analogues Act, that would extend the temporary class-wide scheduling of fentanyl-related substances for two years and also require the Department of Justice to conduct a scientific and medical evaluation of these substances to encourage research so that the scientific and medical communities can study and develop treatments for fentanyl-related substances. Read more here.

Study Reveals Inaccurate Labeling of Marijuana as Hemp
According to a study by the National Institute of Justice, most hemp products advertised as having less than 0.3 percent THC technically fit the federal classification of marijuana. Read more here.

Senators Questions FDA’s Response to Opioid Epidemic
Senators James Lankford (R-OK), Roger Marshall, M.D. (R-KS), Shelley Moore Capito (R-WV), and Marsha Blackburn (R-TN) sent a letter to the US Food and Drug Administration (FDA) on October 19 questioning the agency’s response to stopping the opioid epidemic. Read more here.

**DEA Proposes Increasing Production of Research Marijuana, Psychedelic Substances For Clinical Trials**
The DEA wants to more than double marijuana production for research purposes in 2023, according to a filing in the Federal Register. The agency is also proposing production increases of psychedelic substances for clinical trials, including LSD, psilocybin and mescaline. Read more here.